Coherus Oncology (CHRS) Inventory (2018 - 2026)

Coherus Oncology has disclosed Inventory across 9 years of filings, most recently posting $5.7 million for Q2 2026.

• In Q2 2026, Inventory rose 25.57% year-over-year to $5.7 million; the TTM figure through Jun 2026 stood at $5.7 million (up 25.57% YoY), while the FY2025 annual figure was $3.2 million, down 24.6% from the prior year.
• Inventory came in at $5.7 million for Q2 2026 at Coherus Oncology, up from $4.8 million in the prior quarter.
• In the past five years, Inventory ranged from a high of $66.8 million in Q3 2023 to a low of $2.0 million in Q3 2025.
• Average Inventory over 5 years is $32.1 million, with a median of $34.3 million recorded in 2022.
• Year-over-year, Inventory soared 140.93% in 2023 and slumped 95.7% in 2025.
• Over 5 years, Inventory stood at $38.8 million in 2022, then soared by 61.39% to $62.6 million in 2023, then sank by 93.28% to $4.2 million in 2024, then retreated by 24.6% to $3.2 million in 2025, then jumped by 78.66% to $5.7 million in 2026.
• Per Business Quant data, the three most recent Inventory figures were $5.7 million in Q2 2026, $4.8 million in Q1 2026, and $3.2 million in Q4 2025.